Abstract 46P
Background
Breast cancer is one of the malignant diseases with the highest prevalence around the world, including Indonesia. Data from Global Cancer Statistics 2018 (GLOBOCAN) predicted that up to 2.1 billion women were diagnosed with breast cancer; therefore, it became one of the top four cancerous diseases in women. Several studies have revealed the role of CD36 molecule in breast cancer and there are several gaps in CD36 expression knowledge. In tumor adhesion, CD36 is involved in cellular interaction with collagen in the extracellular matrix. Some measurement methods of CD36 expression molecules include gene expression measurement through micro-assay, total RNA analysis, and plasma examination through ELISA techniques already done in subjects with non alcoholic fatty liver disease, diabetes mellitus, insulin resistance, coronary arterial disease, carotid atherosclerosis, chronic kidney disease, and ischaemic stroke. However, concentration measurement of CD36 plasma molecule in breast cancer using ELISA technique has not yet been done in previous studies.
Methods
This is a cross-sectional study, was held during June 2018 up to February 2019. Sampling methods were taken consecutively in 118 subjects, consisted of 76 BC subjects, 42 normal subjects. Inclusion criteria included women aged 18 to 70 years old, having pathological invasive breast cancers, and subjects were willing to sign the informed consent sheets. Exclusion criteria included subjects with disease progressivity during therapy, diabetes mellitus, stroke, liver, coronary arterial disease, chronic kidney disease. Subjects were then drawn 2 cc of the peripheral blood,and then was centrifuged in 3000 RPM for 15 minutes. After that, the plasma was analyzed with ELISA technique with reagent (Bioassay Technology Laboratory). Data was analyzed using SPSS for windows version 20.
Results
Table: 46P
Profile of plasma CD36 concentration
Characteristic | Median concentration CD36 (ng/mL) | p |
---|---|---|
BC Healthy | 0.21 (-0.05 up to 0.70) 0.57 (0.13 up to 1.05) | 0.00 |
Metastatic BC Non metastatic BC | 0.21 (-0.05 up to 0.70) 0.21 (-0.05 up to 0.70) | > 0.05 |
BC with LN metastatic BC without LN metastatic | 0.20 (-0.05 up to 0.70) 0.23 (-0.05 up to 0.70) | > 0.05 |
Luminal tumor HER2 tumor Triple negative tumor | 0.21 (-0.05 up to 0.67) 0.21 (-0.02 up to 0.70) 0.22 (-0.02 up to 0.36) | > 0.05 |
G1 G2 G3 Unknown grade | 0.23 (0.16 up to 0.70) 0.21 (-0.05 up to 0.70) 0,20 (-0,02 up to 0,67) 0.22 (0.10 up to 0.53) | > 0.05 |
Tumor size > 2 cm Tumor size ≤ 2 cm | 0.21 (-0.05 up to 0.70) 0.26 (0.13 up to 0.70) | > 0.05 |
BC with BMI≥ 23 BC with BMI < 23 | 0.20 (-0.05 up to 0.70) 0.23 (-0.05 up to 0.70) | > 0.05 |
Conclusions
Plasma CD36 concentration of breast cancer is lower than the healthy. There are insignificant differences of plasma CD36 concentration profile breast cancer patients based on metastatic status, lymph node metastatic, molecular subtype, invasive cancer histologic grade, and body mass index.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The Ethics Committee of The Faculty of Medicine, University of Indonesia.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
175P - Hypermethylation of the PCDHB15 promoter predicts the prognosis in gastric cancer
Presenter: Yu-ting Lee
Session: Poster display session
Resources:
Abstract
176P - DCLK1 promotes tumour invasion and metastasis through epithelial-mesenchymal transition and the MEK/ERK pathway in esophageal squamous cell carcinoma
Presenter: Jiannan Yao
Session: Poster display session
Resources:
Abstract
177P - Comparison of nab-paclitaxel plus ramcirumab and paclitaxel plus ramcirumab in patients with pretreated metastatic gastric cancer
Presenter: Yosuke Horita
Session: Poster display session
Resources:
Abstract
178P - Chief cell in stomach have stem cell activity and potential to develop gastric cancer
Presenter: Akihiro Yamamura
Session: Poster display session
Resources:
Abstract
179P - Postoperative Adjuvant transarterial chemoembolization versus surgery alone for resected hepatocellular carcinoma: A propensity-score matching study
Presenter: Mingyu Chen
Session: Poster display session
Resources:
Abstract
180P - LHPP inhibit the cell proliferation and EMT via the TGFβ/SMAD3 signaling pathway in iCCA
Presenter: Dan Wang
Session: Poster display session
Resources:
Abstract
181P - The emerging role of third-line gemcitabine plus nab-paclitaxel in advanced pancreatic adenocarcinoma
Presenter: Andrew Dean
Session: Poster display session
Resources:
Abstract
182P - Durable response to second-line m-FOLFIRINOX for advanced pancreatic adenocarcinoma in patients with performance status of two or less
Presenter: Adarsh Das
Session: Poster display session
Resources:
Abstract
183P - Epidemiologic profile of gastric cancer in East Azerbaijan, Iran: 2 years population-based cancer registry results
Presenter: Pooneh Jabbaripour
Session: Poster display session
Resources:
Abstract
184P - Expression pattern of CDK12 protein in gastric cancer and its positive correlation with CD8+ cell density and CCL12 expression
Presenter: Jun Ji
Session: Poster display session
Resources:
Abstract